Omnicell, Inc. (NasdaqGS:OMCL) entered into a definitive agreement to acquire FDS Amplicare for approximately $180 million on July 25, 2021. Purchase price is subject to customary adjustments. Omnicell will use cash available on its balance sheet to fund the transaction. FDS Amplicare recorded approximately $29 million of total revenue (unaudited) for the 12 months ended June 30, 2021. Acquisition is subject to customary closing conditions, including Hart-Scott-Rodino clearance. The transaction is expected to close in the second half of 2021. Upon closing, the transaction is expected to be immediately accretive to Omnicell’s non-GAAP EBITDA and non-GAAP earnings per share. Evercore served as financial advisor and provided a fairness opinion to Omnicell and Sidley Austin LLP served as legal counsel to Omnicell. Baird served as financial advisor to FDS Amplicare, and Neil Townsend and David Cosgrove of Willkie Farr & Gallagher served as legal counsel to FDS Amplicare. The Evercore team included Eduardo Mestre, Mark Hanson, Bill Anderson, Ted Omlid, AJ Berens, Dave Cahoy and Vincent Cao. A Sidley Austin LLP team led by Sara Garcia Duran and Jennifer Fitchen served as Omnicell s counsel. Omnicell, Inc. (NasdaqGS:OMCL) completed the acquisition of FDS Amplicare on September 9, 2021. Under the terms of the transaction, the estimated closing cash is $0.86 million and assumed indebtedness is of $0.65 million.